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Abstract: In the present study, the authors reported on a case in neuropsychiatric syndromes 
of systemic lupus erythematosus (NPSLE) with irreversible organic brain changes. The authors 
also longitudinally investigated serum brain-derived neurotrophic factor (BDNF) levels in the 
patient. We found that serum BDNF levels in the NPSLE patient with irreversible organic brain 
change were consistently low, independent of the severity of psychiatric symptoms. Thus, the 
longitudinal measurement of serum BDNF levels might be useful in predicting the prognosis 
of NPSLE.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a critical mediator of neuronal 
development, survival, and function (Lewin and Barde 1996). In addition, BDNF is 
currently considered to modulate and regulate immune functions (Vega et al 2003; 
Nockher and Renz 2003). Recently, it has been reported that BDNF is associated with 
the pathogenesis of several neuropsychiatric diseases such as schizophrenia (Hori et al 
2007), depression (Yoshimura et al 2007), multiple sclerosis (Weinstock-Guttman et al 
2007), cerebral ischemia (Berger et al 2004), encephalomyelitis (Chiaretti et al 2004), 
Alzheimer’s disease (Laske et al 2006), Huntington’s chorea (Ciammola et al 2007), 
and Parkinson’s disease (Howells et al 2000).
Systemic lupus erythematosus (SLE) is a multisystem immune disease 
characterized by several abnormalities of the cellular immune system, including a 
loss of B cell tolerance and the production of pathogenic autoantibodies (Shlomchik 
et al 1994). Between 18% and 67% of patients with SLE exhibit central nervous 
system involvement, which is associated with inﬂ  ammatory features in the brain. 
Neuropsychiatric syndromes of SLE (NPSLE) patients often reveal various psychiatric 
features such as delirium, cognitive blunting, psychosis, and affective disorder 
(ACR 1999). Recently, we had reported that serum BDNF levels were increased 
in the presence of severe psychiatric symptoms and organic changes in the brain 
(Ikenouchi et al 2006). In that case, serum BDNF levels were normalized in parallel 
with recovering organic brain changes and improving their associated psychotic 
symptoms. Here we report a case of NPSLE with irreversible organic brain changes. 
Interestingly, the serum BDNF levels were continuously low in spite of the severity 
of psychiatric symptoms.Neuropsychiatric Disease and Treatment 2008:4(6) 1278
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Case report
A 58-year-old man in a delirious state was admitted to the 
psychiatric ward at our university hospital. The patient 
had been diagnosed with SLE 11 years before, based on 
the presence of polyarthritis, photosensitivity, discoid, 
antinuclear antibodies, anti-Sm antibodies, pleuritis, and 
leucopenia. Six years later, he was codiagnosed with 
antiphospholipid syndrome. The patient had been treated 
with predonisolone and cyclophosphamide pulse therapy. On 
admission to the psychiatric ward (Day 0), he had insomnia, 
mood swings, agitation, paranoia, memory dysfunction, 
cognitive impairments and attention deﬁ  cit. His magnetic 
resonance imaging (MRI) scan showed old left cerebeller 
infarctions and lacunar infarctions in the bilateral basal 
ganglia (Figure 1A). Furthermore the patient’s single photon 
emission computed tomography (SPECT) images showed 
an area of hypoperfusion in the bilateral frontal region 
(Figure 1B). The immunoglobulin G (IgG) index and the 
levels of interleukin-6 (IL-6) in his level of cerebrospinal 
ﬂ  uid (CSF) were 0.6 and 28 pg/mL, respectively (Day 0). 
In addition, the results of patient’s CSF were cell count 
3/μL, protein 93 mg/dL, and glucose 55 mg/dL. In addition, 
findings in blood cell count and electrolysis were not 
particular. Thus, the possibility for encephalitis was ruled 
out. Based on the results of these clinical examinations and 
imaging studies, the patient was diagnosed with delirium 
due to NPSLE and/or treatment with prednisolone. His IgG 
index and CSF IL-6 level were 0.6 and 28 pg/mL, respec-
tively. When the patient experienced a delirious episode; his 
scores on the Delirium Rating Scale Revised 98 (DRS-R-98) 
(Trzepacz et al 2001) and the mini-mental state examination 
(MMSE) were 39 and 16, respectively. His serum BDNF 
level was 4.5 ng/mL (Day 1 after admission). Although the 
dose of prednisolone had decreased from 55 to 20 mg/day 
and cyclophosphamide pulse therapy had been completed 
because the activity of NPSLE was subsided, his delirious 
episode persisted. Treatment with quetiapine was initiated, 
and the dose was gradually increased up to 750 mg/day 
to treat his psychotic symptoms including the delirious 
episode. His delirium and paranoia subsided with quetiapine 
treatment. His DRS-R-98 scores were 9, 8, and 2 at 1, 
2, and 4 weeks, respectively after quetiapine administration. 
However, mood swing was persisted. Thus, valproic acid 
was added to quetiapine and the dosage was increased to 
900 mg/day (plasma valproic acid level: 56.8 mEq/L). 
Insomnia, mood swing, agitation, and attention deﬁ  cits 
were gradually improved. However, cognitive impairments 
(memory disturbance, visuospatial skill and learning) 
persisted after recovery of the delirium and psychosis. 
His MMSE score remained at 16 points. His MRI scan and 
SPECT did not improve (Day 92 after admission) (Figure 
2A and 2B). His serum BDNF levels were 4.6 ng/mL (Day 
14 after admission) 1.0 ng/mL (Day 38 after admission), 
1.5 ng/mL (Day 70 after adminission). The IgG index and 
CSF IL-6 level of the patients were 0.51 and 1.9 pg/mL, 
respectively (Day 38 after admission). One month later, his 
mental condition was stable with valproic acid (900 mg/day) 
and quetiapine (750 mg/day), his cognitive impairment 
(particularly memory impairment and apraxia) gradually had 
decreased (his serum BDNF level was 0.8 ng/mL).
Discussion
We presented a case of NPSLE with predominant symptoms 
of delirium and psychosis, which responded well to 
treatment with quetiapine and valproic acid. However, 
memory disturbance and cognitive impairment persisted. 
The interesting ﬁ  nding was that the patient with NPSLE 
and irreversible organic brain changes demonstrated 
consistently low serum BDNF levels in spite of the severity of 
psychiatric symptoms. We have recently reported that serum 
BDNF levels in healthy volunteers and patients with major 
depression were 23.4 ± 10.1 ng/mL, and 9.6 ± 7.7 ng/mL, 
respectively. Therefore, serum BDNF levels in the present 
case were lower compared with those in normal volunteers 
and even in depressed patients. In contrast, in a case of 
NPSLE with reversible organic brain changes, we reported 
that the plasma BDNF levels were raised during the period 
when the patient’s psychotic symptoms deteriorated, and the 
plasma BDNF levels were normalized in parallel with the 
recovery of her organic brain changes and improvement in 
her psychotic symptoms (Ikenouchi et al 2006). In addition, 
Frey and colleagues (2006) reported that long term treatment 
with valproic acid increased hippocampal BDNF levels in 
rats, and Park and colleagues (2006) demonstrated that long 
term quetiapine administration attenuated the decreased 
BDNF mRNA expression in both the hippocampal and corti-
cal regions of rats caused by immobilization stress. In short, 
we consider that treatment with valproic acid and quetiapine 
generally promotes BDNF synthesis in the brain. These ﬁ  nd-
ings show that a transient raise in serum/plasma BDNF levels 
during psychotic symptoms might indicate the possibility of 
nerve recovery, in other words, reversal of brain damage. In 
contrast, consistently low serum/plasma levels in spite of 
psychotic symptoms, while a patient is undergoing treatment 
with valproic acid and quetiapine might reﬂ  ect neuronal loss 
of NPSLE. Furthermore, we cannot completely rule out the Neuropsychiatric Disease and Treatment 2008:4(6) 1279
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Figure 1. MRI (A) and SPECT (B) ﬁ  ndings in day 0 after administration demonstrating old left cerebeller infarctions and lacunar infarctions exist in the bilateral basal ganglia 
in MRI and an area of hypoperfusion in bilateral frontal region was found in SPECT.
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Figure 2. MRI (A) and SPECT (B) ﬁ  ndings in day 92 after administration demonstrating not signiﬁ  cant changes in MRI and SPECT.Neuropsychiatric Disease and Treatment 2008:4(6) 1280
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possibility that prednisolone treatment decreased serum 
BDNF levels in this case. Indeed, chronic stress decreased 
BDNF expression in the brain via enhanced corticosteroid 
release (Jaconsen and Mork 2006). However, serum BDNF 
levels were at consistently low levels after prednisolone 
was decreased. Taken together, it is plausible that the 
BDNF dynamics may differ between NPSLE patients with 
irreversible organic brain changes and those with reversible 
ones. Since the patient did not gain signiﬁ  cant amounts 
of weight over the course of treatment, it is unlikely that 
decreased serum BDNF levels might due to hyperphagia 
(Hashimoto et al 2005).
Experimental evidences in rodents suggest that the effect 
of BDNF on psychiatric symptoms differ with respect to 
brain region. For example, reduced BDNF in the mesolimbic 
dopamine system is associated with improvement in anxiety 
and depressive-like behaviors while increased BDNF in the 
hippocampal formation is associated with antidepressant 
efﬁ  cacy and cognitive function (Berton et al 2006; Chhatwal 
et al 2006; Martinowick et al 2007).
Recently, Oroszi and colleagues (2006) have reported that 
the association between of BDNF Met66 confers protection 
against the decline of motor and psychomotor cognitive 
function in SLE patients suggesting that carriers of the Met66 
polymorphism mat be protected from NPSLE. On the other 
hand, this allele shows a decrease in activity-dependent 
secretion and its associated with poorer cognitive function 
and smaller hippocampal volume (Egan et al 2003). The 
discrepancy between these two ﬁ  ndings remains unknown. 
It is plausible that the role of BDNF in the pathophysiology 
of SLE might be complicated.
The source of circulating BDNF remains unknown. 
Platelet, brain neurons, and vascular endothelial cells 
are currently considered to be putative sources. It was 
demonstrated that BDNF cross the blood–brain barrier (Pan 
et al 1998) and that BDNF levels in the brain and serum have 
been shown to undergo similar changes during the maturation 
and aging process in rats (Karege et al 2002). These results 
indicate that blood BDNF levels might in part reﬂ  ect the 
BDNF levels in the brain. Nonetheless, it remains unclear to 
what extent peripheral levels reﬂ  ect brain BDNF levels.
In conclusion, the ﬁ  nding in the present case indicates 
that keeping low serum BDNF levels may be associated with 
the poor prognosis of NPSLE. Further research is needed to 
conﬁ  rm the present ﬁ  nding.
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